News

Lawxpart/New

This cancer-fighting biotech sped from startup to IPO filing in 10 months

This cancer-fighting biotech sped from startup to IPO filing in 10 months

The team that took Kite Pharma from a startup re-engineering a patient’s own cells to fight cancer to a $12 billion buyout now is seeking a $100 million initial public offering for the South San Francisco company it launched only 10 months ago. Arie Belldegrun and David Chang co-founded Allogene Therapeutics Inc. to develop off-the-shelf cells derived from healthy donors that could be used in a variety of cancer patients. And in moving quickly, Allogene has relied on friends in key places, including…

read more
S.F. drone startup aborts mission after exhausting $118 million in funding

S.F. drone startup aborts mission after exhausting $118 million in funding

San Francisco-based Airware, once sky high with ambition, has halted operations, despite pumping $118 million of investment into its drone operating system. The aerial intelligence company told employees Friday that it would shutter immediately, running out of cash flow “after trying to manufacture its own hardware that couldn’t compete with drone giants like China’s DJI,” TechCrunch reports. Top investors in the startup included Andreessen Horowitz, Google’s GV and Kleiner Perkins. The…

read more
Anaplan files to go public after snagging ex-Tesla exec as finance chief

Anaplan files to go public after snagging ex-Tesla exec as finance chief

San Francisco-based Anaplan filed an IPO prospectus on Friday. The software company joins the growing number of Bay Area tech enterprises filing to go public this year, including SurveyMonkey, DocuSign and Zuora. Goldman Sachs & Co. LLC and Morgan Stanley & Co. LLC are leading the offering, with the number of shares and price range yet to be determined. Founded in 2006, the company, which provides business planning software in the cloud, now has more than 20 offices worldwide, 175 partners and…

read more

Mr John Smith

-Customer

“Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur.”

Mr John Smith

-Customer

“Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur.”

Call us Free

If you would like to speak with someone directly

500.250.1234

Free Consulting